Publications & Reports

Carbohydrate/peptide mimics: effect on MUC1 cancer immunotherapy.

Apostolopoulos V, Sandrin MS, McKenzie IF
Austin Research Institute, Heidelberg, Victoria, Australia.


Recent clinical studies with mannan mucin immunotherapeutic agents indicate that patients produce predominantly antibody responses while mice produce a high cytotoxic T lymphocyte response. In studying the reason for the ‘immune deviation’ occurring in mice to humans from cellular to antibody responses, it has been found that natural anti-Galalpha(1,3)Gal antibodies, present in all humans, react with the mucin component of the agent, providing an example of a carbohydrate-peptide mimic. The immune deviation can be overcome by in vitro sensitization of antigen-presenting cells in the absence of anti-Gal antibodies - at least in mice. The review examines the background of these observations and discusses other peptide carbohydrate mimics and immune deviation


  • Journal: Journal of Molecular Medicine
  • Published: 01/05/1999
  • Volume: 77
  • Issue: 5
  • Pagination: 427-436